MX2024012445A - Terapias de combinacion que comprenden un inhibidor de sos1 y un inhibidor de egfr - Google Patents

Terapias de combinacion que comprenden un inhibidor de sos1 y un inhibidor de egfr

Info

Publication number
MX2024012445A
MX2024012445A MX2024012445A MX2024012445A MX2024012445A MX 2024012445 A MX2024012445 A MX 2024012445A MX 2024012445 A MX2024012445 A MX 2024012445A MX 2024012445 A MX2024012445 A MX 2024012445A MX 2024012445 A MX2024012445 A MX 2024012445A
Authority
MX
Mexico
Prior art keywords
inhibitor
egfr
combination therapies
sos1
therapies including
Prior art date
Application number
MX2024012445A
Other languages
English (en)
Spanish (es)
Inventor
Jacob Haling
Shilpi Khare
Original Assignee
Mirati Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mirati Therapeutics Inc filed Critical Mirati Therapeutics Inc
Publication of MX2024012445A publication Critical patent/MX2024012445A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2024012445A 2022-04-08 2024-10-07 Terapias de combinacion que comprenden un inhibidor de sos1 y un inhibidor de egfr MX2024012445A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263329090P 2022-04-08 2022-04-08
PCT/US2023/015097 WO2023196086A2 (en) 2022-04-08 2023-03-13 Combination therapies comprising a sos1 inhibitor and an egfr inhibitor

Publications (1)

Publication Number Publication Date
MX2024012445A true MX2024012445A (es) 2024-11-08

Family

ID=88243368

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024012445A MX2024012445A (es) 2022-04-08 2024-10-07 Terapias de combinacion que comprenden un inhibidor de sos1 y un inhibidor de egfr

Country Status (10)

Country Link
US (1) US20250177410A1 (https=)
EP (1) EP4504171A4 (https=)
JP (1) JP2025512999A (https=)
KR (1) KR20240170920A (https=)
CN (1) CN119031916A (https=)
AU (1) AU2023250819A1 (https=)
CA (1) CA3245678A1 (https=)
IL (1) IL315645A (https=)
MX (1) MX2024012445A (https=)
WO (1) WO2023196086A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022271679A1 (en) * 2021-06-21 2022-12-29 Mirati Therapeutics, Inc. Sos1 inhibitors
WO2025090810A1 (en) * 2023-10-25 2025-05-01 Kumquat Biosciences Inc. Use of sos1 inhibitors and amivantamab to treat cancer
WO2025090808A1 (en) * 2023-10-25 2025-05-01 Kumquat Biosciences Inc. Combinations of sos-1 inhibitors with osimertinib and/or met inhibitors to treat cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1833803A4 (en) * 2005-01-03 2009-08-05 Myriad Genetics Inc PHARMACEUTICAL COMPOUNDS AS ACTIVATORS OF CASPASES AND INDUCTORS OF APOPTOSIS AND THEIR USE
WO2016077793A1 (en) * 2014-11-14 2016-05-19 Children's Hospital Medical Center Sos1 inhibitors for cancer treatment
EP3558979B1 (en) * 2016-12-22 2021-02-17 Boehringer Ingelheim International GmbH Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors
PH12022551513A1 (en) * 2019-12-20 2023-04-24 Mirati Therapeutics Inc Sos1 inhibitors
WO2022083657A1 (zh) * 2020-10-20 2022-04-28 苏州泽璟生物制药股份有限公司 取代苯并或吡啶并嘧啶胺类抑制剂及其制备方法和应用
CA3221608A1 (en) * 2021-06-14 2022-12-22 Kumquat Biosciences Inc. Fused heteroaryl compounds useful as anticancer agents

Also Published As

Publication number Publication date
CA3245678A1 (en) 2023-10-12
JP2025512999A (ja) 2025-04-22
US20250177410A1 (en) 2025-06-05
IL315645A (en) 2024-11-01
WO2023196086A2 (en) 2023-10-12
EP4504171A4 (en) 2026-03-18
WO2023196086A3 (en) 2023-12-07
EP4504171A2 (en) 2025-02-12
AU2023250819A1 (en) 2024-09-26
CN119031916A (zh) 2024-11-26
KR20240170920A (ko) 2024-12-05

Similar Documents

Publication Publication Date Title
MX2024012445A (es) Terapias de combinacion que comprenden un inhibidor de sos1 y un inhibidor de egfr
MX2024004215A (es) Terapias combinadas de inhibidores de kras g12d con inhibidores de sos1.
MX2024009727A (es) Terapias de combinacion.
BR112023000687A2 (pt) Métodos e combinações de inibidores de kat6 para o tratamento de câncer
CL2024001607A1 (es) Métodos para tratar cánceres y potenciar la eficacia de agentes terapéuticos para el redireccionamiento de células t.
EP4552631A3 (en) Combination of dasatinib and adagrasib for use in the treatment of non-small cell lung cancer
MX2024008551A (es) Terapias de combinacion.
MX2021005011A (es) Métodos de tratamiento del cáncer en pacientes identificados por biomarcadores con inhibidores no covalentes de cinasa 7 dependiente de ciclina (cdk7).
BR112021021713A2 (pt) Método de tratamento de câncer ou inibição do crescimento de um tumor
EP4085919A3 (en) Compositions and methods to treat cancer
EA200970317A1 (ru) Комбинированное лечение опухолей, экспрессирующих cd38
BR112022017724A2 (pt) Inibidores de egfr, kras, braf e outros alvos e uso dos mesmos
MX2024004213A (es) Combinaciones de inhibidores de kras g12d con inhibidores de pi3ka y métodos de tratamiento relacionados.
MX2024004216A (es) Terapias combinadas de inhibidores de kras g12d con inhibidores de la familia pan erbb.
MX2020011684A (es) Inhibicion combinada de pd-1/pd-l1, tgfbeta y dna-pk para el tratamiento del cancer.
CL2022002410A1 (es) Terapia combinada de inhibidores axl/mer y pd-1/pd-l1.
MX2021013317A (es) Terapias de combinacion que comprenden inhibidores de apremilast y tyk2.
BR112023005160A2 (pt) Terapia de combinação para o tratamento de câncer
WO2021133653A8 (en) Therapy for the treatment of cancer
MX2019011506A (es) Inhibicion de cinasa 1 de punto de control (chk1) para el tratamiento de cancer.
MX2024004214A (es) Combinaciones de inhibidores de kras g12d con irinotecán y métodos de tratamiento relacionados.
MX2025013118A (es) Tratamiento combinado para una enfermedad o un trastorno relacionado con ras
WO2021262696A3 (en) Methods for selecting and treating cancer with fgfr3 inhibitors
MX2024012446A (es) Terapias de combinacion que comprenden un inhibidor de sos1 y un inhibidor de mek
MX2025002424A (es) Combinacion de dcc-3116 e inhibidores de la via mapkap para su uso en el tratamiento del cancer